What You Should Know:
– Tempus AI, Inc., a technology company focused on advancing precision medicine with AI, has acquired Paige, an AI company specializing in digital pathology.
– The acquisition, valued at $81.25M, paid predominantly in Tempus common stock, is a strategic move to grow Tempus’s dataset, expand its technical team, and strengthen its position in digital pathology.
A Comprehensive Dataset and Pioneering AI Applications
Since its founding in 2017, Paige has developed and deployed several AI applications, including the first FDA-cleared AI application in pathology. These tools help researchers and pathologists detect cancer more effectively, enabling care teams to make more precise and informed treatment decisions.
Paige has built its products using a dataset of almost 7 million digitized pathology slide images and their associated clinical and molecular data. The data, which is stripped of patient identifiers to protect privacy, spans 45 countries and includes a diverse range of genders, races, ethnicities, and regions. Leveraging this comprehensive dataset, Paige has also created the first million-slide foundation model for cancer, which helps researchers and life sciences companies better understand pathology data and advance drug discovery and development. With this acquisition, Tempus is also assuming Paige’s remaining commitment under its existing Microsoft Azure cloud services agreement.
According to Eric Lefkofsky, Founder and CEO of Tempus, the acquisition will “substantially accelerate” the company’s efforts to build the largest foundation model ever created in oncology. He believes that both the Paige team, with its deep generative AI experience, and the dataset it has built will be catalytic to all of Tempus’s AI initiatives.
